Navigating the co-prescription of clozapine and fluvoxamine

Clozapine is a unique atypical antipsychotic with demonstrated superior efficacy in the medical management of treatment-resistant schizophrenia (Siskind et al., 2016). Its effects are attributed to clozapine itself and to its active metabolite N-desmethylclozapine (norclozapine), with the latter being responsible for many side effects encountered with clozapine therapy (L égaré et al., 2013). Clozapine plasma level monitoring is used to optimise clozapine therapy. A clozapine plasma level above 350 microgram/litre (μg/L) should be achieved (Gee and Howes, 2016).

Source: Schizophrenia Research - September 28, 2018 Category: Psychiatry Authors: Gordon Shymko, Vaughan Clark, Liana Shymko, Flavie Waters Tags: Letter to the Editor Source Type: research